<DOC>
	<DOC>NCT01747278</DOC>
	<brief_summary>Evaluation the efficacy and safety profile of trimethoprim/sulfamethoxazole as Pneumocystis carinii pneumonia (PCP) prophylaxis in Patients With Connective Tissue Diseases (CTD) treated with high-dose glucocorticoids and immunosuppressive agents. Open-labeled, randomized, prospective single-center clinical trial. Observation period of 12 weeks.</brief_summary>
	<brief_title>Study of Trimethoprim/Sulfamethoxazole as PCP Prophylaxis in CTD Patients</brief_title>
	<detailed_description />
	<mesh_term>Pneumonia</mesh_term>
	<mesh_term>Pneumonia, Pneumocystis</mesh_term>
	<mesh_term>Connective Tissue Diseases</mesh_term>
	<mesh_term>Sulfamethoxazole</mesh_term>
	<mesh_term>Trimethoprim</mesh_term>
	<criteria>Age 1865 years with informed consent SLE, Sjögren syndrome, Polymyositis or Dermatomyositis, defined by consensus classification criteria concomitant high dose glucocorticoid, defined as &gt;1mg/kg/d prednisone or equivalent concomitant cyclophosphamide, cyclosporine or mycophenolate mofetil Pregnant or lactating WBC＜ 4×10^9/L，PLT＜100×10^9/L Serum ALT or AST &gt; 2 times upper limit of normal Serum creatinine &gt; 1.5 mg/dL Severe hepatic, hematological, gastrointestinal, pulmonary, cardiovascular, neurological, endocrine or cerebral disease Active infection, including HIV, HCV, HBV, tuberculosis or PCP concomitant antibiotics other than trimethoprim/sulfamethoxazole Patient with malignancy Drug allergy, especially trimethoprim/sulfamethoxazole</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>65 Years</maximum_age>
	<verification_date>December 2012</verification_date>
	<keyword>Pneumocystis carinii pneumonia</keyword>
	<keyword>prophylaxis</keyword>
	<keyword>trimethoprim/sulfamethoxazole</keyword>
</DOC>